31884470|t|Bacillus Subtilis Delays Neurodegeneration and Behavioral Impairment in the Alzheimer's Disease Model Caenorhabditis Elegans.
31884470|a|Multiple causes, apart from genetic inheritance, predispose to the production and aggregation of amyloid-beta (Abeta) peptide and Alzheimer's disease (AD) development in the older population. There is currently no therapy or medicine to prevent or delay AD progression. One novel strategy against AD might involve the use of psychobiotics, probiotic gut bacteria with specific mental health benefits. Here, we report the neuronal and behavioral protective effects of the probiotic bacterium Bacillus subtilis in a Caenorhabditis elegans AD model. Aging and neuronal deterioration constitute important risk factors for AD development, and we showed that B. subtilis significantly delayed both detrimental processes in the wild-type C. elegans strain N2 compared with N2 worms colonized by the non-probiotic Escherichia coli OP50 strain. Importantly, B. subtilis alleviated the AD-related paralysis phenotype of the transgenic C. elegans strains CL2120 and GMC101 that express, in body wall muscle cells, the toxic peptides Abeta3-42 and Abeta1-42, respectively. B. subtilis-colonized CL2355 worms were protected from the behavioral deficits (e.g., poor chemotactic response and decreased body bends) produced by pan-neuronal Abeta1-42 expression. Notably, B. subtilis restored the lifespan level of C. elegans strains that express Abeta to values similar to the life expectancy of the wild-type strain N2 fed on E. coli OP50 cells. The B. subtilis proficiencies in quorum-sensing peptide (i.e., the Competence Sporulation Factor, CSF) synthesis and gut-associated biofilm formation (related to the anti-aging effect of the probiotic) play a crucial role in the anti-AD effects of B. subtilis. These novel results are discussed in the context of how B. subtilis might exert its beneficial effects from the gut to the brain of people with or at risk of developing AD.
31884470	0	17	Bacillus Subtilis	Species	1423
31884470	25	42	Neurodegeneration	Disease	MESH:D019636
31884470	47	68	Behavioral Impairment	Disease	MESH:D001523
31884470	76	95	Alzheimer's Disease	Disease	MESH:D000544
31884470	102	124	Caenorhabditis Elegans	Species	6239
31884470	256	275	Alzheimer's disease	Disease	MESH:D000544
31884470	277	279	AD	Disease	MESH:D000544
31884470	380	382	AD	Disease	MESH:D000544
31884470	423	425	AD	Disease	MESH:D000544
31884470	480	488	bacteria	Species	629395
31884470	617	634	Bacillus subtilis	Species	1423
31884470	640	662	Caenorhabditis elegans	Species	6239
31884470	663	665	AD	Disease	MESH:D000544
31884470	683	705	neuronal deterioration	Disease	MESH:D009410
31884470	744	746	AD	Disease	MESH:D000544
31884470	779	790	B. subtilis	Species	1423
31884470	857	867	C. elegans	Species	328850
31884470	895	900	worms	Species	
31884470	932	953	Escherichia coli OP50	Species	637912
31884470	975	986	B. subtilis	Species	1423
31884470	1002	1004	AD	Disease	MESH:D000544
31884470	1013	1022	paralysis	Disease	MESH:D010243
31884470	1051	1061	C. elegans	Species	328850
31884470	1070	1076	CL2120	CellLine	CVCL:K881
31884470	1081	1087	GMC101	CellLine	CVCL:J815
31884470	1187	1198	B. subtilis	Species	1423
31884470	1209	1215	CL2355	CellLine	CVCL:L945
31884470	1216	1221	worms	Species	
31884470	1381	1392	B. subtilis	Species	1423
31884470	1424	1434	C. elegans	Species	328850
31884470	1537	1544	E. coli	Species	562
31884470	1545	1549	OP50	CellLine	CVCL:DG77
31884470	1561	1572	B. subtilis	Species	1423
31884470	1590	1596	quorum	Chemical	-
31884470	1655	1658	CSF	Gene	1437
31884470	1791	1793	AD	Disease	MESH:D000544
31884470	1805	1816	B. subtilis	Species	1423
31884470	1874	1885	B. subtilis	Species	1423
31884470	1987	1989	AD	Disease	MESH:D000544

